GANX

1.78

3.26% -0.06

Dopo l'orario di chiusura: 1.81 0.03 +1.69%

Gain Therapeutics Inc (GANX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GANX Giù? Forum Previsione

Precedente Chiudi:

$1.84

Aprire:

$1.85

Volume 24 ore:

382.89K

Relative Volume:

0.55

Capitalizzazione di mercato:

$77.69M

Reddito:

$55,200

Utile/perdita netta:

$-21.24M

Rapporto P/E:

-3.0246

EPS:

-0.5885

Flusso di cassa netto:

$-19.37M

1 W Prestazione:

+1.14%

1M Prestazione:

-6.56%

6M Prestazione:

-9.18%

1 anno Prestazione:

+2.89%

Intervallo 1D:

$1.775

$1.8827

Intervallo di 1 settimana:

$1.775

$1.9733

Portata 52W:

$1.53

$4.34

Gain Therapeutics Inc Stock (GANX) Company Profile

Nome

Gain Therapeutics Inc

Settore

Healthcare (1067)

Industria

Biotechnology (595)

Telefono

(301) 500-1556

Indirizzo

4800 HAMPDEN LANE, BETHESDA

Dipendente

Cinguettio

Prossima data di guadagno

2026-11-11

Ultimi documenti SEC

GANX's Discussions on Twitter

Compare GANX vs VRTX, REGN, MRNA, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GANX Gain Therapeutics Inc	1.78	77.69M	55,200	-21.24M	-19.37M	-0.5885
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-07	Iniziato	Scotiabank	Sector Outperform
2024-12-06	Iniziato	ROTH MKM	Buy
2024-08-14	Ripresa	Oppenheimer	Outperform
2021-04-12	Iniziato	BTIG Research	Buy
2021-04-12	Iniziato	Oppenheimer	Outperform

Gain Therapeutics Inc Borsa (GANX) Ultime notizie

Sep 18, 2026

Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca

Sep 18, 2026

Sep 17, 2026

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference - investingnews.com

Sep 17, 2026

Gain Therapeutics Announces CEO Gene Mack to Participate in ROTH Healthcare Opportunities Conference Panel and One-on-One Meetings - Quiver Quantitative

Sep 17, 2026

Sep 14, 2026

HLS Therapeutics Inc. (TSX:HLS) Gains Momentum as Cardiovascular Growth and Balance Sheet Improvement Support Investor Confidence - kalkine.ca

Sep 14, 2026

Sep 09, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com

Sep 09, 2026

Aug 31, 2026

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Aug 31, 2026

H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 31, 2026

Aug 30, 2026

GANX Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates Despite Share SlipAnalyst Drop Coverage - dars.gov.et

Aug 30, 2026

Aug 25, 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network

Aug 25, 2026

Aug 24, 2026

Gain (GANX) Price: Moves 0.25% Lower to $2.00 in the Latest Reading; Levels: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotFactor Timing - dars.gov.et

Aug 24, 2026

Aug 21, 2026

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance

Aug 21, 2026

Aug 19, 2026

Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn

Aug 19, 2026

Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 19, 2026

Aug 18, 2026

Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn

Aug 18, 2026

GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat

Aug 18, 2026

Aug 15, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 15, 2026

Aug 14, 2026

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 14, 2026

Aug 13, 2026